Back to search

Article

Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety Perspective

2026-06-11

Abstract excerpt

Chimeric antigen receptor T-cell (CAR-T) therapy represents a transformative yet high-cost immunotherapeutic strategy that has benefited many patients with hematological malignancies and autoimmune diseases. As of January 2025, only a limited number of CAR-T products have received approval by the FDA, EMA, and the NMPA, primarily targeting CD19 or B-cell maturation antigen (BCMA) expressed on cancer cells. The man...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
56f2aab6-d8ba-5d68-9f3f-84f112f58925
DOI
10.20944/preprints202509.1093.v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveDOI 10.20944/preprints202509.1093.v2
Lentivirus for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity
Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity
Clinical use of lentiviral vectorsSemantic proximity
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology PatientsSemantic proximity
Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity
Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity
Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 yearsSemantic proximity
Engineering of CAR-less lentiviral vectors via ER retention-mediated CAR blockadeSemantic proximity
Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene EditingSemantic proximity
Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In VivoSemantic proximity
Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona CaseSemantic proximity
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T CellsSemantic proximity
Select a neighboring publication to make it the new centre.